$AMD

This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Advanced Micro Devices (NASDAQ:AMD)

Analysts upgraded five companies: UBS raised Fluence Energy's (FLNC) target to $12, Morgan Stanley boosted Dynatrace's (DT) target to $65, Raymond James upgraded AMD (AMD) to Strong Buy with a $641 target, Bernstein increased Summit Therapeutics' (SMMT) target to $11.9, and Wells Fargo raised Shift4 Payments' (FOUR) target to $59.

Original reporting
Published Aug 25, 2026, 1:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 2:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMarket movers
Primary signal
$AMD
Bullish
high confidence
Mentioned
$AMD · $FLNC · $DT · $SMMT · $FOUR
Relevance
5/10
alphai data visualization · based on benzinga.com
Decision brief

The 30-second read

$AMDBullishMed
01

Why it matters

Collective upgrades signal a generally positive bias from sell-side analysts, potentially prompting short-term buying pressure.

02

Market read

Upgrades across multiple stocks may create sector momentum, especially in tech and payments.

03

What to watch

Potential macro headwinds could dampen the impact of these upgrades.

Relevance 5/10Novelty 6/10Timing: same-day upgrade

Background

The article aggregates recent analyst rating upgrades for several U.S.-listed companies.

Company-level read

Ticker impact

$AMDBullishHigh confidence
Context

Raymond James upgraded AMD to Strong Buy with a new price target of $641.

Expected impact

Potential short-term upside as analysts raise target.

Evidence & confidence

Strong Buy rating and higher target suggest improved outlook.

$FLNCNeutralMedium confidence
Context

UBS upgraded Fluence Energy to Neutral and raised target to $12.

Expected impact

Limited upside unless further catalysts emerge.

Evidence & confidence

Upgrade is modest; price target modestly higher than current price.

$DTBullishMedium confidence
Context

Morgan Stanley upgraded Dynatrace to Overweight with target $65.

Expected impact

Likely modest rally toward new target.

Evidence & confidence

Higher weight and target indicate confidence in growth.

$SMMTBullishLow confidence
Context

Bernstein upgraded Summit Therapeutics to Market Perform, target $11.9.

Expected impact

Potential incremental gain.

Evidence & confidence

Small target increase; biotech remains volatile.

$FOURBullishMedium confidence
Context

Wells Fargo upgraded Shift4 Payments to Overweight, target $59.

Expected impact

Possible short-term rally.

Evidence & confidence

Higher weight and target suggest better outlook.

Market effects

Analyst upgrades may lift sentiment across the technology and payments sectors.

U.S. equity markets could see modest gains in related stocks.

Limited to U.S.-listed companies; minimal global effect.

Counterpoint

Upgrades may be premature if underlying fundamentals remain weak.

Key entities

  • Raymond James

    Provided AMD upgrade.

  • UBS

    Provided Fluence Energy upgrade.

Related articles

$AMDLow

AMD has released 'ROCm 10,' which enhances the AI processing capabilities of AMD GPUs, and has also introduced 'ROCm.AI,' which provides skills and other resources for AI development.

AMD released ROCm 10, a GPU computing software stack, and ROCm.AI, an AI-driven development platform. The updates aim to enhance AI processing capabilities of AMD GPUs and compete with NVIDIA's CUDA. Key features include optimizations for image and video generation, and tools like AMD Skills and Hyperloom to reduce developer workload.

$SMMTHighAI 8/10

Summit Therapeutics (SMMT) Is Up 8.5% After Ivonescimab’s Phase III Biliary Cancer Survival Win

Summit Therapeutics (SMMT) rose 8.5% after partner Akeso's Phase III trial showed ivonescimab plus chemotherapy improved survival rates in advanced biliary tract cancer. The drug's success adds to its lung cancer data and ongoing FDA review. Summit projects $897.3M revenue and $169.7M earnings by 2029, with analysts estimating potential $2.5B revenue by 2029.